CRBU FY2024 EPS Increased by Brookline Capital Management

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Research analysts at Brookline Capital Management upped their FY2024 earnings per share (EPS) estimates for Caribou Biosciences in a note issued to investors on Wednesday, November 6th. Brookline Capital Management analyst L. Cann now expects that the company will earn ($1.66) per share for the year, up from their prior estimate of ($1.76). The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.71) per share. Brookline Capital Management also issued estimates for Caribou Biosciences' Q4 2024 earnings at ($0.39) EPS, FY2025 earnings at ($2.91) EPS and FY2027 earnings at ($3.80) EPS.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The firm had revenue of $2.02 million during the quarter, compared to analyst estimates of $3.37 million.

Several other equities analysts have also recently issued reports on the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $14.00 price target on shares of Caribou Biosciences in a report on Wednesday, August 7th. HC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Caribou Biosciences in a report on Tuesday, September 3rd.

Caribou Biosciences Stock Performance

Shares of NASDAQ:CRBU traded up $0.07 during midday trading on Monday, reaching $2.75. The company's stock had a trading volume of 1,004,591 shares, compared to its average volume of 1,716,463. Caribou Biosciences has a fifty-two week low of $1.50 and a fifty-two week high of $8.33. The business's fifty day simple moving average is $2.01 and its 200-day simple moving average is $2.27.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CRBU. Allspring Global Investments Holdings LLC boosted its stake in shares of Caribou Biosciences by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 42,653 shares of the company's stock worth $219,000 after acquiring an additional 3,594 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Caribou Biosciences by 32.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 230,192 shares of the company's stock valued at $1,097,000 after purchasing an additional 56,586 shares during the period. Susquehanna Fundamental Investments LLC bought a new stake in Caribou Biosciences in the 1st quarter valued at $558,000. Entropy Technologies LP bought a new stake in Caribou Biosciences in the 1st quarter valued at $113,000. Finally, Vanguard Group Inc. boosted its stake in Caribou Biosciences by 3.8% in the 1st quarter. Vanguard Group Inc. now owns 4,110,795 shares of the company's stock valued at $21,129,000 after purchasing an additional 148,751 shares during the period. Institutional investors and hedge funds own 77.51% of the company's stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.